Reproductive Factors and Subtypes of Breast Cancer Defined by Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2: A Register-Based Study From Korea

Lee, Jung Sun; Oh, Minkyung; Ahn, Seung-Ho; Bae, Jinhee; Bae, Yun‐Jung; Baek, Jin-A; Bong, Jin Gu; Cha, Kyoungho; Chang, Enqiang; Chang, Ilsung; Chang, Sue-Ling; Cho, J.W.; Cho, S.H.; Cho, Y.U.; Choi, Ji‐Yeob; Choi, Kyujin; Choi, Mi-Sun; Choi, Sukwoo; Choi, Seung Young; Goo, G.S.; Han, Shuwen; Han, Wonshik; Hong, Sung‐Eun; Hwang, J.Y.; Hyun, T.I.; Jegal, Young Jong; Im, Muir; Joh, Yong Geul; Jun, Si-Youl; Jung, Bom; Jung, Jiwoong; Jung, Kyung-Hae; Jung, Pa Jong; Jung, Sung Hoo; Jung, Sang Seol; Jung, Young Hoon; Jung, Yongsik; Kang, Dong‐Hyun; Kang, Hee Joon; Kang, Youngmo; Kang, Yujia; Keum, Ji-Soo; Kim, D.Y.; Kim, H.J.; Kim, J.G.; Kim, J.H.; Kim, J.S.; Kim, K.C.; Kim, S.C.; Kim, S.H.; Kim, S.I.; Kim, S.J.; Kim, S.W.; Kim, S.Y.; Kim, Y.S.; Ko, Byung Kyun; Ko, Sun-Hye; Koh, Suk Hwan; Koo, Bum-Hwan; Koo, Jocelyn; Kwak, Byung Kook; Lee, C.H.; Lee, D.H.; Lee, D.S.; Lee, E.S.; Lee, G.S.; Lee, H.D.; Lee, H.S.; Lee, J.C.; Lee, J.H.; Lee, J.K.; Lee, J.S.; Lee, J.Y.; Lee, K.M.; Lee, K.P.; Lee, K.S.; Lee, K.Y.; Lee, M.H.; Lee, R.A.; Lee, S.C.; Lee, S.J.; Lee, S.K.; Lee, W.; Lee, Y.H.; Leu, Jiuan-Shin; Lim, C-u; Lim, Cheol Wan; Moon, Byung In; Nam, Yeonju; Nam, Seungyoon; Noh, Dong‐Young; Noh, Woo-Chul; Oh, Se Jeong; Oh, Sunhwa; Pae, Won Kil; Paik, In-Wook; Paik, Nam-Sun; Park, B.G.; Park, B.W.; Park, C.H.; Park, H.B.; Park, H.Y.; Park, Ji H.; Park, K.H.; Park, S.J.; Park, S.T.; Park, S.W.; Park, W.C.; Park, Y.K.; Seo, Hye‐Sook; Seo, Ki Hyun; Seo, Young Jin; Sin, Youngjoo; Son, Byung Ho; Son, Gil Soo; Song, Byung Joo; Song, Kyoung Ho; Song, Yuwei; Suh, Yelin; Won, Jae-Kyung; Woo, Duck-Soo; Yang, Danting; Yang, Jian; Yoo, Keun Young; Yoo, Suk Young; Yoon, Hyun Sun; Yoon, Jung Han; Yoon, Seungtai

doi:10.1016/j.clbc.2014.05.003

Cited by 20 publications

(21 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The distribution of the 4 major subtypes in the SeBCS was comparable with the distribution in the data of the Korean Breast Cancer Society Registry, in which the percentage of each subtype was 54.9%, 11.4%, 12.1%, and 21.6%, respectively. 13 …”

Section: Methodsmentioning

confidence: 99%

Attribution to Heterogeneous Risk Factors for Breast Cancer Subtypes Based on Hormone Receptor and Human Epidermal Growth Factor 2 Receptor Expression in Korea

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Attribution to Heterogeneous Risk Factors for Breast Cancer Subtypes Based on Hormone Receptor and Human Epidermal Growth Factor 2 Receptor Expression in Korea

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In a Korean study, parity of five or more increased the risk of luminal A and B breast cancer (HR 1.95, 95% CI, 0.96-3.97, p=0.0055; and HR 1.12; 95% CI, 0.42-3.02, p=0.0073 respectively) and an early age of first birth (less than 20 years) was associated with increased risk of luminal A BC recurrence (HR 1.61, 95% CI, 0.62-4.26; p=0.039). However, between one and three childbirths was associated with decreased risk of luminal A and B (HR, 0.56; 95% CI, 0.34-0.91, p= 0.0055; and HR, 0.32; 95% CI, 0.17-0.61, p=0.0073 respectively) ( Lee and Oh, 2014). In India, women with BC, had a higher age at last child birth, lower mean duration of breastfeeding, and a higher number of abortions compared to women who did not have BC (Bhadoria et al, 2013).…”

Section: Reproductive History and Breastfeedingmentioning

confidence: 99%

“…BC risk was found to decrease in women with history of full-term pregnancy (Pei et al, 2014). However, one study noted that increased parity and early age at first birth were associated with increased risk of BC recurrence (Lee and Oh, 2014).…”

Section: Modifiable Risk Factorsmentioning

confidence: 99%

A Review of the Epidemiology of Breast Cancer in Asia: Focus on Risk Factors

Youn

Han

2020

Asian Pac J Cancer Prev

104

View full text Add to dashboard Cite

Background and Aim: Breast cancer is the most prevalent cancer in women. To date, regional differences in breast cancer risk factors have not been identified. The aim of our review was to gain a better understanding of the role of risk factors in women with breast cancer in Asia. Methods: We conducted a PubMed search on 15 March 2016, for journal articles published in English between 2011 and 2016, which reported data for human subjects in Asia with a diagnosis of breast cancer. Search terms included breast neoplasm, epidemiology, Asia, prevalence, incidence, risk and cost of illness. Studies of any design were included, except for review articles and meta-analyses, which were excluded to avoid duplication of data. No exclusions were made based on breast cancer treatment. We reported the results using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Results: A total of 776 abstracts were retrieved. After screening against the eligibility criteria, 562 abstracts were excluded. The remaining 214 abstracts, which were published between 2013 and 2015, were included in this review. Results were summarized and reported under three categories: incidence, prevalence or outcomes for breast cancer in Asia; modifiable risk factors; and non-modifiable risk factors. We found that the increased risk of breast cancer among participants from Asia was associated with older age, family history of breast cancer, early menarche, late menopause, high body mass index, being obese or overweight, exposure to tobacco smoke, and high dietary intake of fats or fatty foods. In contrast, intake of dietary fruits, vegetables, and plant-and soy-based products was associated with a decreased breast cancer risk. While based on limited data, when compared to women from the United States, women from Asia had a decreased risk of breast cancer. Conclusions: This review of 214 abstracts of studies in Asia, published between 2013 and 2015, confirmed the relevance of known non-modifiable and modifiable risk factors for women with breast cancer.

show abstract

“…Conventional oral formulations of NFD are required to be administered in multiple doses and therefore have several disadvantages because of its short elimination half-life (Lee et al, 1999;Li et al, 2009). For example, use of short-acting nifedipine was associated with increased risk of stroke occurrence in elderly hypertensive patients (Lee et al, 2011). To increase therapeutic index and reduce side effects, more attention has been focused on the development of NFD oral sustained (controlled) release delivery system.…”

Section: Introductionmentioning

confidence: 99%

Development and pharmacokinetic evaluation of once-daily sustained-released matrix capsules of nifedipine using solid dispersion technique

Zheng¹

2013

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

The purpose of this study was to develop once-daily sustained-release matrix capsules of nifedipine (F1) using the combination of solid dispersion and drug controlled release techniques. F1 were prepared by the wetting granules methods using hydroxypropyl methyl cellulose (HPMC) as hydrophilic retard drug release agent and ethylcellolulose (EC) ethanol solution based on the polyvinyl pyrrolidone / stearic acid solid dispersion. In vitro drug release kinetic model of F1 was fitted well with the zeroorder kinetic equation: Q=0.0736 t+0.0871 (R=0.993) in the range of 0-6 h, the first-order kinetic equation: Ln (1-Q) =-0.0934 t-0.1375 (R=0.999) in the range of 6-24 h, respectively. The relative bioavailability of F1 was studied in rabbits after oral administration using a commercial available controlled release tablet (F2) as a reference. The pharmacokinetic results showed no significant differences in Cmax, MRT and AUC (0-24h). The relative oral bioavailability value from F1 in comparison with F2 was 97.12 %. The results of both in vitro and in vivo studies indicated that once-daily sustainedrelease matrix capsules of NFD prepared by the optimized formulation exhibited excellent sustainedrelease effects and high relative oral bioavailability.

show abstract

Reproductive Factors and Subtypes of Breast Cancer Defined by Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2: A Register-Based Study From Korea

Cited by 20 publications

References 48 publications

Attribution to Heterogeneous Risk Factors for Breast Cancer Subtypes Based on Hormone Receptor and Human Epidermal Growth Factor 2 Receptor Expression in Korea

Attribution to Heterogeneous Risk Factors for Breast Cancer Subtypes Based on Hormone Receptor and Human Epidermal Growth Factor 2 Receptor Expression in Korea

A Review of the Epidemiology of Breast Cancer in Asia: Focus on Risk Factors

Development and pharmacokinetic evaluation of once-daily sustained-released matrix capsules of nifedipine using solid dispersion technique

Contact Info

Product

Resources

About